MitoQ for Multiple Sclerosis (MitoQ Trial)

Recruiting in Palo Alto (17 mi)

Overseen ByVijayshree Yadav, MBBS

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: VA Office of Research and Development

Trial Summary

What is the purpose of this trial?The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

Eligibility Criteria

This trial is for MS patients with persistent fatigue and an MFIS score of 38 or higher. They must have been diagnosed by the McDonald criteria, have an EDSS score between 2 to 8, and not be severely depressed. People can't join if they've used steroids recently, are pregnant/breastfeeding, have certain health issues like heart or liver disease, or were on MitoQ/CoQ10 in the last month.

Inclusion Criteria

I have been feeling tired for at least two months.

I have been diagnosed with multiple sclerosis according to the 2017 criteria.

My disability score is between 2 and 8.

Exclusion Criteria

I do not have any major health issues that could worsen by participating in this study.

I have had a major MS flare-up in the last month.

Participant Groups

The study tests if MitoQ reduces fatigue in MS patients compared to a placebo. Participants will either take a daily dose of MitoQ (20mg or 40mg) or a placebo for 12 weeks. Their levels of fatigue at the start and after treatment will show if there's any improvement.

3Treatment groups

Active Control

Placebo Group

Group I: 20mg of MitoQActive Control1 Intervention

20mg of oral mitoquinol

Group II: 40mg of MitoQActive Control1 Intervention

40mg of Oral Mitoquinol

Group III: PlaceboPlacebo Group1 Intervention

Placebo